Technetium 99m-labeled tetrofosmin and iodine 123-labeled metaiodobenzylguanidine scintigraphy in the assessment of transmyocardial laser revascularization

被引:6
作者
Muxí, A
Magriñá, J
Martín, F
Josa, M
Fuster, D
Setoain, FJ
Pérez-Villa, F
Pavia, J
Bosch, X
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Ctr Diagnost Imatge, Nucl Med Serv, Barcelona, Spain
[2] Inst Malalties Cardiovasc, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
关键词
D O I
10.1016/S0022-5223(02)73271-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Transmyocardial laser revascularization is a new technique that improves symptoms in patients with refractory angina not amenable to conventional revascularization. The aim of this study was to assess whether transmyocardial laser revascularization produces changes in innervation, perfusion scintigraphy, or both that could explain the benefit to patients. Methods: Sixteen patients (12 men and 4 women; mean age, 60 +/- 8 years) with coronary artery disease were studied. Transmyocardial laser revascularization was performed in 39 myocardial areas supplied by a stenotic vessel. A technetium 99m-labeled tetrofosmin stress-rest tomographic scan and iodine 123-labeled meta-iodobenzylguanidine planar scans were performed before and after transmyocardial laser revascularization (3 and 12 months later) to evaluate myocardial perfusion and innervation. Stress and rest perfusion images were quantified on a polar map. Ischemia uptake was also defined as the difference between rest and stress uptake for each area. Innervation planar images were visually analyzed and semiquantified. Results: A significant decrease in angina class from baseline was observed at 3, 6, and 12 months after transmyocardial laser revascularization (P < .005). A significant decrease in ischemia uptake was also found between the pre-transmyocardial laser revascularization and the post-transmyocardial laser revascularization studies in treated areas (P < .001). A significant improvement in stress myocardial perfusion at 3 and 12 months after transmyocardial laser revascularization was only found in treated areas that were considered ischemic in the pre-transmyocardial laser revascularization study (P < .05). At 3 months, a significant myocardial innervation worsening was observed in treated areas (P < .001), with partial recovery at 12 months (P < .05). Conclusion: The transmyocardial laser revascularization mechanism involves both perfusion improvement and denervation, mainly at 3 months, that partially recovered at 12 months.
引用
收藏
页码:1493 / 1498
页数:6
相关论文
共 24 条
[1]   Cardiac sympathetic denervation after transmyocardial laser revascularization [J].
Al-Sheikh, T ;
Allen, KB ;
Straka, SP ;
Heimansohn, DA ;
Fain, RL ;
Hutchins, GD ;
Sawada, SG ;
Zipes, DP ;
Engelstein, ED .
CIRCULATION, 1999, 100 (02) :135-140
[2]   Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina [J].
Allen, KB ;
Dowling, RD ;
Fudge, TL ;
Schoettle, GP ;
Selinger, SL ;
Gangahar, DM ;
Angell, WW ;
Petracek, MR ;
Shaar, CJ ;
O'Neill, WW .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14) :1029-1036
[3]   Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial [J].
Burkhoff, D ;
Schmidt, S ;
Schulman, SP ;
Myers, J ;
Resar, J ;
Becker, LC ;
Weiss, J ;
Jones, JW .
LANCET, 1999, 354 (9182) :885-890
[4]  
Chu Victor, 1999, Journal of the American College of Cardiology, V33, p342A
[5]   Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis [J].
Cohen-Solal, A ;
Esanu, Y ;
Logeart, D ;
Pessione, F ;
Dubois, C ;
Dreyfus, G ;
Gourgon, R ;
Merlet, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :759-766
[6]   Transmyocardial laser revascularization: Clinical experience with twelve-month follow-up [J].
Cooley, DA ;
Frazier, OH ;
Kadipasaoglu, KA ;
Lindenmeir, MH ;
Pehlivanoglu, S ;
Kolff, JW ;
Wilansky, S ;
Moore, WH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (04) :791-799
[7]   Symptomatic improvement after transmyocardial laser revascularization: How long does it last? [J].
De Carlo, M ;
Milano, AD ;
Pratali, S ;
Levantino, M ;
Mariotti, R ;
Bortolotti, U .
ANNALS OF THORACIC SURGERY, 2000, 70 (03) :1130-1133
[8]   Transmyocardial laser revascularization using the holium-YAG laser for treatment of end stage coronary artery disease [J].
Diegeler, A ;
Schneider, J ;
Lauer, B ;
Mohr, FW ;
Kluge, R .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1998, 13 (04) :392-397
[9]  
Estorch M, 1999, J NUCL MED, V40, P911
[10]  
ESTORCH M, 1998, EUR J NUCL MED, V25, P1003